晚期上皮性卵巢癌治疗更新与新选择
本文综述晚期上皮性卵巢癌医学与手术治疗策略的演变。多项里程碑临床试验推动靶向治疗广泛应用,多腺苷二磷酸核糖聚合酶抑制剂改善一线及复发 settings 的无进展生存,基因检测指导治疗分类。手术在复发患者中的角色受到新数据质疑,临床试验入组仍至关重要。
要点
- 所有上皮性卵巢癌患者均应行胚系基因检测
- PARP抑制剂改善一线和复发患者的无进展生存
- 复发患者手术角色受新数据质疑,临床试验入组仍极重要
核心结论
- 晚期上皮性卵巢癌治疗持续演变,靶向治疗日益广泛,PARP抑制剂改善一线及复发无进展生存,临床试验入组仍至关重要。
主要发现
- PARP抑制剂在初治和复发场景均改善无进展生存结局,其使用日益广泛。
- 基于基因改变的治疗分类强化了所有上皮性卵巢癌患者行胚系基因检测的推荐。
- 新的生物标志物驱动药物获批提示患者可能从体细胞分子检测中获益。
- 新数据对复发疾病患者手术的作用提出质疑。
关键数值与推荐
- 推荐所有上皮性卵巢癌女性进行胚系基因检测。
临床怎么用
- 细胞毒性化疗与最大程度手术仍是主要手段,靶向治疗应更广泛整合。
- 应基于基因检测结果对患者进行分类并选择靶向治疗。
- 复发患者手术决策需结合新证据个体化,并优先考虑临床试验入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The medical and surgical treatment strategies for women with epithelial ovarian cancer continue to evolve. In the past several years, there has been significant progress backed by landmark clinical trials. Although primary epithelial ovarian cancer is still treated with a combination of surgery and systemic therapy, more complex surgical procedures and novel therapeutics have emerged as standard of care. Cytotoxic chemotherapy and maximal surgical effort remain mainstays, but targeted therapies are becoming more widespread and new data have called into question the role of surgery for women with recurrent disease. Poly ADP-ribose polymerase inhibitors have improved progression-free survival outcomes in both the frontline and recurrent settings, and their use has become increasingly widespread. The recent creation of treatment categories based on genetic changes reinforces the recommendation that all women with epithelial ovarian cancer have germline genetic testing, and new biomarker-driven drug approvals indicate that women may benefit from somatic molecular testing as well. To continue to identify novel strategies, however, enrollment on clinical trials remains of the utmost importance. With the evolving data on surgical approaches, targeted therapies such as antiangiogenics and poly ADP-ribose polymerase inhibitors, and the new therapeutic agents and combinations in development, we hope that advanced epithelial ovarian cancer will eventually transition from an almost universally fatal disease to one that can increasingly be cured.
引用
- Kurnit KC, Fleming GF, Lengyel E, et al. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021. PMID: 33278287. doi:10.1097/AOG.0000000000004173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。